Summer 2015

Multiple Myeloma

Matthew Crowley
Otterbein University, matthew.crowley@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn

Part of the Hemic and Lymphatic Diseases Commons, Medical Pathology Commons, and the Nursing Commons

Recommended Citation
Crowley, Matthew, "Multiple Myeloma" (2015). Master of Science in Nursing (MSN) Student Scholarship. 98.
https://digitalcommons.otterbein.edu/stu_msn/98

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital Commons @ Otterbein. It has been accepted for inclusion in Master of Science in Nursing (MSN) Student Scholarship by an authorized administrator of Digital Commons @ Otterbein. For more information, please contact shickey@otterbein.edu.
Multiple Myeloma
Matthew Crowley BSN, RN
Otterbein University, Westerville, Ohio

Introduction

Multiple myeloma is a rare and largely incurable malignant disease that affects the plasma cells. (Blatt, Gleason, McNeill, and the International Myeloma Foundation Nurse Leadership Board, 2011). Understanding the pathophysiology of Multiple Myeloma (MM) and treatment options in Oncology and Hematology nursing can be difficult. It is the goal of this poster to outline the pathophysiology, treatment options available to multiple myeloma patients.

Multiple myeloma accounts for about 10% of hematologic malignancies in the U.S. (Kuo, Fenves, Mehta, 2011). MM is the second most common hematologic malignancy with twenty-four thousand new MM cases each year (Blanchi, and Anderson, 2014).

Pathophysiology

In normal physiology mature plasma cells make up less than 5% of the bone marrow cells. Precursor cells called plasma blasts and B lymphocytes are stimulated by antigens and cytokines then migrate to the bone marrow where they stop proliferating, and begin to differentiate to mature plasma cells (Magen, 2005). The majority of MM is preceded by a premalignant disease known as monoclonal gammopathy of undetermined significance (Muriel, Sauco, Léniz, Ghorbal, and Roccaro, 2012). This monoclonal gammopathy is the expansion of a single clone of plasma cells (Ferreira, 2013). The monoclonal cells crowd out healthy cells.

The proliferation of monoclonal plasma cells accumulates in the marrow which leads to secretion of cytokines by the tumor cells. Here in the microenvironment of the bone marrow the ability of myeloma to live and replicate is thought to occur (Magen, 2005).

The majority of MM patients eventually relapse with all therapeutic approaches currently available (Lawasut, Groen, Dhimolea, et al., 2013). Balance between bone resorption and bone formation is lost in many cases of MM, resulting in bone destruction and the development of bone lesions (Murer et al., 2012). Bone health is a primary concern for MM patients.

Bone pain and fractures

Fatigue

Increased infections

Weakness and fatigue

Restlessness

Confusion

Increased thirst

Nausea and vomiting

Loss of appetite weight loss

Impaired kidney function

Increased or decreased urination

Fatigue is a commonly reported symptom of MM often thought to be a consequence of anemia (Briker, Dixon, Pilarz, Neum, and Babish, 2009). Anemia (mostly normocytic-normochromic) is seen in approximately 75% of patients (Ali, Fani, 2013).

Implications for Nursing Care

Treatment options include the use of monoclonal antibodies against specific surface markers on MM cells (Lawasut et al., 2013). High-dose chemotherapy with autologous stem cell transplantation is the standard of therapy for patients newly diagnosed with multiple myeloma who are younger than age 70 or have no comorbidities (Tariman, and Estrella, 2005). Nursing care occurs in multiple settings. “Nurses provide care and education to patients at all stages of the multiple myeloma (MM) disease continuum, from the premalignant stage and diagnosis all the way through survivorship to the end of life.” (Nioseuti, 2012) Patients present to routine exams, present to emergency department as inpatients who are newly diagnosed. Post diagnosis nurses care involves treatment with chemotherapy, care in medical surgical settings, survivorship, and hospice.

Conclusion

Multiple Myeloma diagnosis and prognosis is viewed as incurable there remains many treatment options based on the stage of cancer, age and comorbidities. Patient goals should always be considered when developing treatment plans and discussing options. Early stages of the disease can yield many years of quality life with current treatments ranging from maintenance/induction to bone marrow transplant.

For end stage disease patients quality of life can be achieved through compassionate nursing care delivered by palliative measures and hospice care.

References